Natera Inc. (NTRA)

NTRA · Health Care · United States

Natera Inc. (NTRA) is a company in the Health Care sector, based in United States. The stock is held in 16 ETFs we track – with its largest weight of 0.77 % in XUHL (msci-usa-health-care). Anyone holding one of these ETFs also owns a small indirect stake in Natera.

Above-average ETF coverage: 16 of the 95 ETFs we cover hold Natera, spread across 7 indices. That puts the stock in more ETFs than 76.4 % of the 4,334 stocks we cover.

Held in16 ETFs

Highest weight0.77 %

Indices7

SectorHealth Care

CountryUnited States

ISINUS6323071042

Data note 1

Price chart

Data note 2

Performance

Performance
Year to date	+50.7 %	1 year	+97.3 %
1 month	+9.9 %	3 months	+52.5 %
Calendar year 2025	+44.7 %

52W

Data note 3

Measured in euros, Natera returned +53.5 % year to date and +101.9 % over one year. The gap to the dollar figures above comes from the exchange rate alone: each daily price is converted at the ECB euro reference rate for the same day.

Data note 4

Risk metrics

Max drawdown-28.2 %

Volatility p.a.47.0 %

Data note 5

Below peak-1.6 %

Beta to S&P 5001.25

Correlation to S&P 5000.34

The close on Sep 16, 2026 was 1.6 % below the highest close since Aug 12, 2024, reached on Sep 15, 2026. Over the last 252 trading days, on days when the S&P 500 rose or fell 1 %, Natera moved on average 1.25 % in the same direction. The correlation of 0.34 shows how reliable that average is: the broad market explained only a small share of the daily moves.

Data note 6

Correlated with

The strongest co-movers on top, the most inverse below. Low or negative values improve portfolio diversification.

Correlated with
Instrument	r	−1 … +1
Airbnb Inc. Class A	+0.54
Atlassian Corp. Class A	+0.45
Waters Corporation	+0.45
Coeur Mining Inc.	+0.43
Thermo Fisher Scientific Inc.	+0.43
Twilio Inc. Class A	+0.42
HFT	-0.38
Lyondellbasell Industries Class A	-0.35
Targa Resources Corp.	-0.35

Data note 7

Key financials

Latest reported fiscal year (FY2025, period end 2025-12-31) as filed with the SEC.

Revenue2.3 bn $

Net income-0.2 bn $

Diluted EPS-1.52 $

Net margin-9.0 %

Return on equity-12.2 %

Equity ratio71.4 %

Revenue growth+35.9 %

Revenue and profit by fiscal year
Fiscal year	Revenue	Net income	Margin
FY2023	1.1	-0.4	-40.2 %
FY2024	1.7	-0.2	-11.2 %
FY2025	2.3	-0.2	-9.0 %

Data note 8

Held in these ETFs

Held in these ETFs
ETF	Index	Weight	per €1,000 in the ETF
XUHL / XUHC	msci-usa-health-care	0.77 %	€7.70
XDWH	msci-world-health-care	0.56 %	€5.60
SPFS	msci-world-health-care	0.56 %	€5.60
XD9U / XD9D	msci-usa	0.07 %	€0.70
SWWD	msci-world	0.06 %	€0.60
SPPW	msci-world	0.06 %	€0.60
WIMI	msci-world-imi	0.05 %	€0.50
SPYY	msci-acwi	0.05 %	€0.50
EUNL	msci-world	0.05 %	€0.50
XDWD / XDWL	msci-world	0.05 %	€0.50
IUSQ	msci-acwi	0.04 %	€0.40
SPYI / SPSA	msci-acwi-imi	0.03 %	€0.30

Data note 9

The last column turns the weight into euros: this much of €1,000 invested in one of these funds is allocated to Natera as of the fund's latest holdings list.

How much Natera Inc. overlaps with other holdings in a portfolio is shown by the Portfolio X-Ray and the ETF overlap check.

Stocks with similar ETF exposure

Names that reach a portfolio through largely the same funds as Natera — the figure counts the ETFs holding both.

Data note 10

Key figures side by side

Key figures compared with stocks of similar ETF exposure
Stock	1 year	Volatility p.a.	Net margin	Revenue growth
Natera	+97.3 %	47.0 %	-9.0 %	+35.9 %
Insmed Incorporated	-15.3 %	54.9 %	-210.5 %	+66.7 %
Medline	–	45.7 %	4069.4 %	+11.5 %
Neurocrine Biosciences	+6.1 %	36.8 %	16.7 %	+21.4 %
Illumina	+125.6 %	45.3 %	19.6 %	-0.7 %
Roivant Sciences	+179.1 %	39.6 %	-3629.2 %	-71.6 %
Revolution Medicines	+338.3 %	56.9 %	–	–
Boston Scientific Corporation	-55.6 %	31.0 %	–	+19.9 %
Danaher Corporation	+9.4 %	30.6 %	14.7 %	+2.9 %

Return and volatility from our daily closing prices in US dollars; margin and growth from the latest SEC annual filing. Fiscal years do not all end on the same date.